Neuroinflammation

• The Interplay between Cannabinoid Receptors and Microglia in the Pathophysiology of Alzheimer’s Disease (02 Sep 2024)
  
• The Impact of the CB2 Cannabinoid Receptor in Inflammatory Diseases: An Update (02 Sep 2024)
  
• Research progress on the cannabinoid type-2 receptor and Parkinson’s disease (02 Sep 2024)
  
• Exploring the Therapeutic Potential of Cannabinoid Receptor Antagonists in Inflammation, Diabetes Mellitus, and Obesity (02 Sep 2024)
  
• Beta-Caryophyllene, a Cannabinoid Receptor Type 2 Selective Agonist, in Emotional and Cognitive Disorders (02 Sep 2024)
  
• The Role of Cannabinoid Type 2 Receptors in Parkinson’s Disease (27 Aug 2024)
  
• Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential (27 Aug 2024)
  
• Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders (25 Aug 2024)
  
• Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer’s disease symptoms: a case report (25 Aug 2024)
  
• Roles of the Cannabinoid System in the Basal Ganglia in Parkinson’s Disease (21 Aug 2024)
  
• New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders (21 Aug 2024)
  
• Epigenetic Regulation of Cannabinoid-Mediated Attenuation of Inflammation and Its Impact on the Use of Cannabinoids to Treat Autoimmune Diseases (20 Aug 2024)
  
• Cannabinoid Drugs-Related Neuroprotection as a Potential Therapeutic Tool Against Chemotherapy-Induced Cognitive Impairment (20 Aug 2024)
  
• Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson’s Disease (19 Aug 2024)
  
• Modulation of Astrocyte Activity by Cannabidiol, a Nonpsychoactive Cannabinoid (18 Aug 2024)
  
• CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease (18 Aug 2024)
  
• Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson's Disease (18 Aug 2024)
  
• A helping HAND: therapeutic potential of MAGL inhibition against HIV-1-associated neuroinflammation (24 May 2024)
  
• Effects of Cannabidiol on Innate Immunity: Experimental Evidence and Clinical Relevance (27 Feb 2023)
  
• Endocannabinoid Metabolism and Traumatic Brain Injury (01 Sep 2022)
  
• CB2 Receptor in Microglia: The Guardian of Self-Control (01 Sep 2022)
  
• Reviewing the Role of the Endocannabinoid System in the Pathophysiology of Depression (27 Aug 2022)
  
• The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation (05 Aug 2022)
  
• Cannabinoids Reduce Extracellular Vesicle Release from HIV-1 Infected Myeloid Cells and Inhibit Viral Transcription (05 Aug 2022)
  
• Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty (31 Jul 2022)